iX Biopharma Ltd. is a specialty pharmaceutical
company, with a focus on the development and
commercialisation of innovative therapies for
improving the lives of those suffering from pain
and other health issues. The Company leverages
its patented sublingual drug delivery technology,
WaferiX™, to develop proprietary products that
incorporate pharmacologically active compounds
that have been approved by regulatory bodies. Its
current pipeline of products include Wafermine™,
BnoX™ and Wafernyl™ for pain management,
PheoniX™ for erectile dysfunction, and WafeRest™
for improved sleep quality.
iX Biopharma operates a fully-integrated business
model from drug development to manufacturing
and supply. Its manufacturing facility in Australia is
approved by the Therapeutic Goods Administration
of Australia, complies with Good Manufacturing
Practice, and supplies drugs to hospitals and
registered pharmacies under Schedule 5A of the
Therapeutic Goods Regulations 1990 of Australia.
6 Oct 2016
No comments:
Post a Comment